

Summary of Analysis Sets  
(All Participants Randomized)

	Placebo n (%)	Xanomeline line Low Dose n (%)	Xanomeline line High Dose n (%)
Participants in Population	86	84	84
Participants included in ITT population	86 (100.0)	84 (100.0)	84 (100.0)
Participants included in efficacy population	79 ( 91.9)	81 ( 96.4)	74 ( 88.1)
Participants included in safety population	86 (100.0)	84 (100.0)	84 (100.0)